Alzheimer's disease (AD) is a neurodegenerative disease with progressive loss of memory and cognitive function. Because its pathogenesis has not been fully elucidated, there is still a lack of understanding of its pathogenesis and effective treatment. Many studies have shown that Mesenchymal stem cells Exosomes (MSCs-Exo) can promote anti-inflammatory, regulate immune function, enhance amyloid (Aβ) degradation, and promote axon growth of nerve cells. Exosomes can effectively cross the blood-brain barrier, and have better biocompatibility and biosafety than nanomaterials, and more diverse ways to carry drugs. Adipose stem cell exosomes can not only treat AD by their own characteristics, but also regulate AD and other neurological diseases as A drug carrier that can efficiently and freely cross the blood-brain barrier: they can effectively reduce Aβ42 plaques and improve the neuronal microenvironment through microglia. In AD model mice, excessive activation of microglia demonstrated the formation of an inflammatory microenvironment in the brain. The inflammatory microenvironment erodes healthy neurons to a certain extent, forcing them to overactivate inflammatory signaling pathways so that they can't function normally, Adipose stem cell exosomes can effectively clear the expression of inflammatory factors in hypoxia-induced AD neuronal model and promote synaptic repair through microRNA/ phosphatase and tensin homolog (miR-223/PTEN) and phosphatidylinositol kinase (PI3K/Akt) pathways. It can promote the polarization of microglia towards anti-inflammatory phenotype and promote neuronal repair. Adipose stem cell exosomes can also be used to improve memory and cognitive dysfunction by alleviating Tau phosphating or delaying hippocampus volume decay, targeting the core pathological mechanism of AD to achieve therapeutic effects. This article mainly introduces the role of MSC exosomes in the pathogenesis and development of AD.
Published in | Biomedical Sciences (Volume 10, Issue 1) |
DOI | 10.11648/j.bs.20241001.12 |
Page(s) | 6-13 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Mesenchymal Stem Cells, Exosomes, Alzheimer’s Disease
[1] | Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022). Staging of Alzheimer's disease: past, present, and future perspectives. Trends in molecular medicine, 28(9), 726–741. |
[2] | Moustaka, K., Nega, C., & Beratis, I. N. (2023). Exploring the Impact of Age of Onset of Mild Cognitive Impairment on the Profile of Cognitive and Psychiatric Symptoms. Geriatrics (Basel, Switzerland), 8(5), 96. |
[3] | Gordon, B. A., Blazey, T. M., Christensen, J., Dincer, A., Flores, S., Keefe, S., Chen, C., Su, Y., McDade, E. M., Wang, G., Li, Y., Hassenstab, J., Aschenbrenner, A., Hornbeck, R., Jack, C. R., Ances, B. M., Berman, S. B., Brosch, J. R., Galasko, D., Gauthier, S., … Benzinger, T. L. S. (2019). Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain: a journal of neurology, 142(4), 1063–1076. |
[4] | Oveisgharan, S., Buchman, A. S., Yu, L., Farfel, J., Hachinski, V., Gaiteri, C., De Jager, P. L., Schneider, J. A., & Bennett, D. A. (2018). APOE ε2ε4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults. Neurology, 90(24), e2127–e2134. |
[5] | Khan, S., Barve, K. H., & Kumar, M. S. (2020). Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease. Current neuropharmacology, 18(11), 1106–1125. |
[6] | Luca, M., Di Mauro, M., Di Mauro, M., & Luca, A. (2019). Gut Microbiota in Alzheimer's Disease, Depression, and Type 2 Diabetes Mellitus: The Role of Oxidative Stress. Oxidative medicine and cellular longevity, 2019, 4730539. |
[7] | Chen, S., Peng, J., Sherchan, P., Ma, Y., Xiang, S., Yan, F., Zhao, H., Jiang, Y., Wang, N., Zhang, J. H., & Zhang, H. (2020). TREM2 activation attenuates neuroinflammation and neuronal apoptosis via PI3K/Akt pathway after intracerebral hemorrhage in mice. Journal of neuroinflammation, 17(1), 168. |
[8] | Zhang, T., Ma, S., Lv, J., Wang, X., Afewerky, H. K., Li, H., & Lu, Y. (2021). The emerging role of exosomes in Alzheimer's disease. Ageing research reviews, 68, 101321. |
[9] | Clayton K, Delpech JC, Herron S, et al. Plaque associated microglia hypersecrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model. Mol Neurodegener 2021; 16: 18. |
[10] | Ruan Z, Pathak D, Venkatesan Kalavai S, et al. Alzheimer’s disease brainderived extracellular vesicles spread tau pathology in interneurons. Brain 2021; 144: 288–309. |
[11] | Joo, Hyeon Su et al. “Exosomes for the diagnosis and treatment of dementia.” Current opinion in psychiatry vol. 36,2 (2023): 119-125. |
[12] | L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, M. J. Wood, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol. 29 (4) (2011) 341–345. |
[13] | Lu, G., Su, X., Wang, L., Leung, C. K., Zhou, J., Xiong, Z., Wang, W., Liu, H., & Chan, W. Y. (2023). Neuroprotective Effects of Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cell Extracellular Vesicles in Ischemic Stroke Models. Biomedicines, 11(9), 2550. |
[14] | Kaniowska, Dorota et al. “Extracellular Vesicles of Mesenchymal Stromal Cells Can be Taken Up by Microglial Cells and Partially Prevent the Stimulation Induced by β-amyloid.” Stem cell reviews and reports vol. 18, 3(2022): 1113-1126. |
[15] | Wang, Han et al. “Tail-vein injection of MSC-derived small extracellular vesicles facilitates the restoration of hippocampal neuronal morphology and function in APP / PS1 mice.” Cell death discovery vol. 7,1 230. 4 Sep. 2021. |
[16] | Sun, Yao et al. “Mesenchymal stem cells-derived exosomes for drug delivery.” Stem cell research & therapy vol. 12,1 561. 30 Oct. 2021. |
[17] | Barage, S. H., & Sonawane, K. D. (2015). Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides, 52, 1–18. |
[18] | Reddy, P. H., Yin, X., Manczak, M., Kumar, S., Pradeepkiran, J. A., Vijayan, M., & Reddy, A. P. (2018). Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer's disease. Human molecular genetics, 27(14), 2502–2516. |
[19] | Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020). Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Molecular neurodegeneration, 15(1), 40. |
[20] | Kreutzer, A. G., Guaglianone, G., Yoo, S., Parrocha, C. M. T., Ruttenberg, S. M., Malonis, R. J., Tong, K., Lin, Y. F., Nguyen, J. T., Howitz, W. J., Diab, M. N., Hamza, I. L., Lai, J. R., Wysocki, V. H., & Nowick, J. S. (2023). Probing differences among Aβ oligomers with two triangular trimers derived from Aβ. Proceedings of the National Academy of Sciences of the United States of America, 120(22), e2219216120. |
[21] | Sebastian Monasor, L., Müller, S. A., Colombo, A. V., Tanrioever, G., König, J., Roth, S., Liesz, A., Berghofer, A., Piechotta, A., Prestel, M., Saito, T., Saido, T. C., Herms, J., Willem, M., Haass, C., Lichtenthaler, S. F., & Tahirovic, S. (2020). Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. eLife, 9, e54083. |
[22] | Uddin, M. S., & Lim, L. W. (2022). Glial cells in Alzheimer's disease: From neuropathological changes to therapeutic implications. Ageing research reviews, 78, 101622. |
[23] | Hampel, H., Mesulam, M. M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain: a journal of neurology, 141(7), 1917–1933. |
[24] | Lee, M., Ban, J. J., Yang, S., Im, W., & Kim, M. (2018). The exosome of adipose-derived stem cells reduces β-amyloid pathology and apoptosis of neuronal cells derived from the transgenic mouse model of Alzheimer's disease. Brain research, 1691, 87–93. |
[25] | Thomi, G., Surbek, D., Haesler, V., Joerger-Messerli, M., & Schoeberlein, A. (2019). Exosomes derived from umbilical cord mesenchymal stem cells reduce microglia-mediated neuroinflammation in perinatal brain injury. Stem cell research & therapy, 10(1), 105. |
[26] | Gratuze, M., Chen, Y., Parhizkar, S., Jain, N., Strickland, M. R., Serrano, J. R., Colonna, M., Ulrich, J. D., & Holtzman, D. M. (2021). Activated microglia mitigate Aβ-associated tau seeding and spreading. The Journal of experimental medicine, 218(8), e20210542. |
[27] | Shmulevich, R., & Krizhanovsky, V. (2021). Cell Senescence, DNA Damage, and Metabolism. Antioxidants & redox signaling, 34(4), 324–334. |
[28] | Nelson, G., Wordsworth, J., Wang, C., Jurk, D., Lawless, C., Martin-Ruiz, C., & von Zglinicki, T. (2012). A senescent cell bystander effect: senescence-induced senescence. Aging cell, 11(2), 345–349. |
[29] | Rothhammer, V., & Quintana, F. J. (2015). Role of astrocytes and microglia in central nervous system inflammation. Introduction. Seminars in immunopathology, 37(6), 575–576. |
[30] | Wei, H., Xu, Y., Chen, Q., Chen, H., Zhu, X., & Li, Y. (2020). Mesenchymal stem cell-derived exosomal miR-223 regulates neuronal cell apoptosis. Cell death & disease, 11(4), 290. |
[31] | Cai, G., Cai, G., Zhou, H., Zhuang, Z., Liu, K., Pei, S., Wang, Y., Wang, H., Wang, X., Xu, S., Cui, C., Sun, M., Guo, S., Jia, K., Wang, X., & Zhang, D. (2021). Mesenchymal stem cell-derived exosome miR-542-3p suppresses inflammation and prevents cerebral infarction. Stem cell research & therapy, 12(1), 2. (Retraction published Stem Cell Res Ther. 2023 Jan 16; 14(1): 9. |
[32] | Wen, L., Wang, Y. D., Shen, D. F., Zheng, P. D., Tu, M. D., You, W. D., Zhu, Y. R., Wang, H., Feng, J. F., & Yang, X. F. (2022). Exosomes derived from bone marrow mesenchymal stem cells inhibit neuroinflammation after traumatic brain injury. Neural regeneration research, 17(12), 2717–2724. |
[33] | Jin, Y., Wang, J., Li, H., Gao, S., Shi, R., Yang, D., Wang, X., Wang, X., Zhu, L., Wang, X., Chen, C., Ning, K., Gao, Z., Xu, J., & Fu, Q. (2018). Extracellular Vesicles Secreted by Human Adipose-derived Stem Cells (hASCs) Improve Survival Rate of Rats with Acute Liver Failure by Releasing lncRNA H19. EBioMedicine, 34, 231–242. |
[34] | Yang, Y., Luo, P., Xu, H., Dai, S., Rao, W., Peng, C., Ma, W., Wang, J., Xu, H., Zhang, L., Zhang, S., & Fei, Z. (2017). RNF146 Inhibits Excessive Autophagy by Modulating the Wnt-β-Catenin Pathway in Glutamate Excitotoxicity Injury. Frontiers in cellular neuroscience, 11, 59. |
[35] | Vaarmann, A., Kovac, S., Holmström, K. M., Gandhi, S., & Abramov, A. Y. (2013). Dopamine protects neurons against glutamate-induced excitotoxicity. Cell death & disease, 4(1), e455. |
[36] | Duan, T. Q., Gao, Z. L., Luo, A. X., Chen, D., Tong, J. B., & Huang, J. F. (2023). Adipose mesenchymal stem cell-derived extracellular vesicles reduce glutamate-induced excitotoxicity in the retina. Neural regeneration research, 18(10), 2315–2320. |
[37] | Kauppi, K., Nilsson, L. G., Adolfsson, R., Eriksson, E., & Nyberg, L. (2011). KIBRA polymorphism is related to enhanced memory and elevated hippocampal processing. The Journal of neuroscience: the official journal of the Society for Neuroscience, 31(40), 14218–14222. |
[38] | Kauwe, G., Pareja-Navarro, K. A., Yao, L., Chen, J. H., Wong, I., Saloner, R., Cifuentes, H., Nana, A. L., Shah, S., Li, Y., Le, D., Spina, S., Grinberg, L. T., Seeley, W. W., Kramer, J. H., Sacktor, T. C., Schilling, B., Gan, L., Casaletto, K. B., & Tracy, T. E. (2023). KIBRA repairs synaptic plasticity and promotes resilience to tauopathy-related memory loss. bioRxiv: the preprint server for biology, 2023. 06. 12. 543777. |
[39] | El Mammeri, Nadia et al. “Microtubule-binding core of the tau protein.” Science advances vol. 8, 29 (2022): eabo4459. |
[40] | Crews, L., & Masliah, E. (2010). Molecular mechanisms of neurodegeneration in Alzheimer's disease. Human molecular genetics, 19(R1), R12–R20. |
[41] | Hashimoto, S., Matsuba, Y., Kamano, N., Mihira, N., Sahara, N., Takano, J., Muramatsu, S. I., Saido, T. C., & Saito, T. (2019). Tau binding protein CAPON induces tau aggregation and neurodegeneration. Nature communications, 10(1), 2394. |
[42] | Tracy, T. E., Sohn, P. D., Minami, S. S., Wang, C., Min, S. W., Li, Y., Zhou, Y., Le, D., Lo, I., Ponnusamy, R., Cong, X., Schilling, B., Ellerby, L. M., Huganir, R. L., & Gan, L. (2016). Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss. Neuron, 90(2), 245–260. |
[43] | Liu, S., Fan, M., Xu, J. X., Yang, L. J., Qi, C. C., Xia, Q. R., & Ge, J. F. (2022). Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology. Journal of neuroinflammation, 19(1), 35. |
[44] | Kannappan, B., Gunasekaran, T. I., Te Nijenhuis, J., Gopal, M., Velusami, D., Kothandan, G., Lee, K. H., & Alzheimer’s Disease Neuroimaging Initiative (2022). Polygenic score for Alzheimer's disease identifies differential atrophy in hippocampal subfield volumes. PloS one, 17(7), e0270795. |
[45] | Xie, X., Song, Q., Dai, C., Cui, S., Tang, R., Li, S., Chang, J., Li, P., Wang, J., Li, J., Gao, C., Chen, H., Chen, S., Ren, R., Gao, X., & Wang, G. (2023). Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer's disease: a phase I/II clinical trial. General psychiatry, 36(5), e101143. |
[46] | Salarinia R, Sahebkar A, Peyvandi M, et al. Epi-Drugs and Epi-miRs: moving beyond current cancer therapies [J]. Curr Cancer Drug Targets, 2016, 16(9): 773-788. |
[47] | Banikazemi Z, Haji HA, Mohammadi M, et al. Diet and cancer prevention: Dietary compounds, dietary MicroRNAs, and dietary EXOsomes [J]. J Cell Biochem, 2018, 119(1): 185-196. |
[48] | Jafari SH, Saadatpour Z, Salmaninejad A, et al. Breast cancer diagnosis: Imaging techniques and biochemical markers [J]. J Cell Physiol, 2018, 233(7): 5200-5213. |
[49] | Baglio SR, Rooijers K, Koppers-Lalic D, et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther. 2015; 6(1): 127. |
[50] | Gámez-Valero A, Campdelacreu J, Vilas D, et al. Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer's disease and dementia with Lewy bodies. Transl Neurodegener. 2019; 8: 31. |
[51] | Giuliani A, Gaetani S, Sorgentoni G, et al. Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimer's Disease. Front Aging Neurosci. 2021; 13: 647015. |
[52] | Walgrave H, Zhou L, De Strooper B, Salta E. The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives. Mol Neurodegener. 2021; 16(1): 76. |
[53] | Feng MG, Liu CF, Chen L, et al. MiR-21 attenuates apoptosis-triggered by amyloid-β via modulating PDCD4/ PI3K/AKT/GSK-3β pathway in SH-SY5Y cells. Biomed Pharmacother. 2018; 101: 1003-1007. |
[54] | Chen YA, Lu CH, Ke CC, et al. MSCs-Exo Ameliorate Alzheimer's Disease Pathology and Improve Cognitive Deficits. Biomedicines. 2021; 9(6): 594. |
[55] | Yao P, Zhou L, Zhu L, Zhou B, Yu Q. Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Neurodegenerative Diseases. Eur Neurol. 2020; 83(3): 235-241. |
[56] | Gorabi AM, Kiaie N, Barreto GE, Read MI, Tafti HA, Sahebkar A. The Therapeutic Potential of MSCs-Exo in Treatment of Neurodegenerative Diseases. Mol Neurobiol. 2019; 56(12): 8157-8167. |
[57] | Friedrich, M., & Aigner, A. (2022). Therapeutic siRNA: State-of-the-Art and Future Perspectives. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy, 36(5), 549–571. |
[58] | Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X. J. (2020). Therapeutic siRNA: state of the art. Signal transduction and targeted therapy, 5(1), 101. |
[59] | Ali Zaidi, S. S., Fatima, F., Ali Zaidi, S. A., Zhou, D., Deng, W., & Liu, S. (2023). Engineering siRNA therapeutics: challenges and strategies. Journal of nanobiotechnology, 21(1), 381. |
[60] | Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., Pang, X., Tao, W., Shimoni, O., Bush, A. I., Xue, X., & Shi, B. (2020). Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer's disease therapy. Science advances, 6(41), eabc7031. |
[61] | Yang, X., Yang, W., Xia, X., Lei, T., Yang, Z., Jia, W., Zhou, Y., Cheng, G., & Gao, H. (2022). Intranasal Delivery of BACE1 siRNA and Rapamycin by Dual Targets Modified Nanoparticles for Alzheimer's Disease Therapy. Small (Weinheim an der Bergstrasse, Germany), 18(30), e2203182. |
[62] | Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021). Nanomaterials for cancer therapy: current progress and perspectives. Journal of hematology & oncology, 14(1), 85. |
[63] | Li, L., Zhang, J., Huang, X., Du, J., Tu, Z., Wu, H., Liu, X., & Yuan, M. (2023). Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease. Current pharmaceutical design, 29(2), 95–115. |
APA Style
Tian, M., Yi, X. (2024). The Role of Mesenchymal Stem Cell Exosomes in the Onset and Progression of Alzheimer's Disease. Biomedical Sciences, 10(1), 6-13. https://doi.org/10.11648/j.bs.20241001.12
ACS Style
Tian, M.; Yi, X. The Role of Mesenchymal Stem Cell Exosomes in the Onset and Progression of Alzheimer's Disease. Biomed. Sci. 2024, 10(1), 6-13. doi: 10.11648/j.bs.20241001.12
AMA Style
Tian M, Yi X. The Role of Mesenchymal Stem Cell Exosomes in the Onset and Progression of Alzheimer's Disease. Biomed Sci. 2024;10(1):6-13. doi: 10.11648/j.bs.20241001.12
@article{10.11648/j.bs.20241001.12, author = {Meng-Si Tian and Xi-Nan Yi}, title = {The Role of Mesenchymal Stem Cell Exosomes in the Onset and Progression of Alzheimer's Disease}, journal = {Biomedical Sciences}, volume = {10}, number = {1}, pages = {6-13}, doi = {10.11648/j.bs.20241001.12}, url = {https://doi.org/10.11648/j.bs.20241001.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bs.20241001.12}, abstract = {Alzheimer's disease (AD) is a neurodegenerative disease with progressive loss of memory and cognitive function. Because its pathogenesis has not been fully elucidated, there is still a lack of understanding of its pathogenesis and effective treatment. Many studies have shown that Mesenchymal stem cells Exosomes (MSCs-Exo) can promote anti-inflammatory, regulate immune function, enhance amyloid (Aβ) degradation, and promote axon growth of nerve cells. Exosomes can effectively cross the blood-brain barrier, and have better biocompatibility and biosafety than nanomaterials, and more diverse ways to carry drugs. Adipose stem cell exosomes can not only treat AD by their own characteristics, but also regulate AD and other neurological diseases as A drug carrier that can efficiently and freely cross the blood-brain barrier: they can effectively reduce Aβ42 plaques and improve the neuronal microenvironment through microglia. In AD model mice, excessive activation of microglia demonstrated the formation of an inflammatory microenvironment in the brain. The inflammatory microenvironment erodes healthy neurons to a certain extent, forcing them to overactivate inflammatory signaling pathways so that they can't function normally, Adipose stem cell exosomes can effectively clear the expression of inflammatory factors in hypoxia-induced AD neuronal model and promote synaptic repair through microRNA/ phosphatase and tensin homolog (miR-223/PTEN) and phosphatidylinositol kinase (PI3K/Akt) pathways. It can promote the polarization of microglia towards anti-inflammatory phenotype and promote neuronal repair. Adipose stem cell exosomes can also be used to improve memory and cognitive dysfunction by alleviating Tau phosphating or delaying hippocampus volume decay, targeting the core pathological mechanism of AD to achieve therapeutic effects. This article mainly introduces the role of MSC exosomes in the pathogenesis and development of AD. }, year = {2024} }
TY - JOUR T1 - The Role of Mesenchymal Stem Cell Exosomes in the Onset and Progression of Alzheimer's Disease AU - Meng-Si Tian AU - Xi-Nan Yi Y1 - 2024/03/13 PY - 2024 N1 - https://doi.org/10.11648/j.bs.20241001.12 DO - 10.11648/j.bs.20241001.12 T2 - Biomedical Sciences JF - Biomedical Sciences JO - Biomedical Sciences SP - 6 EP - 13 PB - Science Publishing Group SN - 2575-3932 UR - https://doi.org/10.11648/j.bs.20241001.12 AB - Alzheimer's disease (AD) is a neurodegenerative disease with progressive loss of memory and cognitive function. Because its pathogenesis has not been fully elucidated, there is still a lack of understanding of its pathogenesis and effective treatment. Many studies have shown that Mesenchymal stem cells Exosomes (MSCs-Exo) can promote anti-inflammatory, regulate immune function, enhance amyloid (Aβ) degradation, and promote axon growth of nerve cells. Exosomes can effectively cross the blood-brain barrier, and have better biocompatibility and biosafety than nanomaterials, and more diverse ways to carry drugs. Adipose stem cell exosomes can not only treat AD by their own characteristics, but also regulate AD and other neurological diseases as A drug carrier that can efficiently and freely cross the blood-brain barrier: they can effectively reduce Aβ42 plaques and improve the neuronal microenvironment through microglia. In AD model mice, excessive activation of microglia demonstrated the formation of an inflammatory microenvironment in the brain. The inflammatory microenvironment erodes healthy neurons to a certain extent, forcing them to overactivate inflammatory signaling pathways so that they can't function normally, Adipose stem cell exosomes can effectively clear the expression of inflammatory factors in hypoxia-induced AD neuronal model and promote synaptic repair through microRNA/ phosphatase and tensin homolog (miR-223/PTEN) and phosphatidylinositol kinase (PI3K/Akt) pathways. It can promote the polarization of microglia towards anti-inflammatory phenotype and promote neuronal repair. Adipose stem cell exosomes can also be used to improve memory and cognitive dysfunction by alleviating Tau phosphating or delaying hippocampus volume decay, targeting the core pathological mechanism of AD to achieve therapeutic effects. This article mainly introduces the role of MSC exosomes in the pathogenesis and development of AD. VL - 10 IS - 1 ER -